---
title: "SL1009 (sodium dichloroacetate): Pyruvate dehydrogenase complex deficiency"
description: "Formulary evidence on SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency. Clinical evidence covers SL1009-01, SL1009-02, Controlled clinical trial of dichloroacetate for congenital lactic acidosis in children, Dichloroacetate randomized controlled trial in MELAS, Long-term safety of dichloroacetate in congenital lactic acidosis, Chronic treatment of mitochondrial disease with dichloroacetate, and 10 further headings. 216 evidence topics quoted from 72 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# SL1009 (sodium dichloroacetate): Pyruvate dehydrogenase complex deficiency

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Sodium dichloroacetate

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Pyruvate dehydrogenase complex deficiency

<a id="topic-1.1.1-1"></a>

##### Summary

The sponsor estimates that PDCD affects fewer than 1,000 individuals in the United States, with an incidence of approximately 1 in 40,000 live births. In a natural-history cohort of 59 participants, 23 (39%) had died; reported causes included severe lactic acidosis, respiratory failure, and infection. A separate neurodevelopmental study reported intellectual disability in 33 of 42 participants (79%) and significant adaptive-functioning impairment in 31 of 35 (89%). These estimates describe different populations and should not be treated as interchangeable measures of prognosis.

Source: [Saol Therapeutics complete response letter announcement (2025)](https://www.prnewswire.com/news-releases/saol-therapeutics-receives-complete-response-letter-from-fda-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-deficiency-pdcd-302548522.html); [DeBrosse et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23021068/); [Savvidou et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13445312/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Sodium dichloroacetate Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

The pivotal SL1009-01 trial enrolled 34 participants. The original observer-reported primary efficacy endpoint was not met. The FDA reported a treatment difference of 0.29, with a 95% confidence interval of -0.62 to 1.21 and p=0.52, favoring placebo. Conference evidence reported reduced plasma lactate with DCA (p=0.006), while the sponsor reported motor improvement during longer treatment, including the open-label extension (p=0.002). These findings do not establish success on the prespecified primary endpoint. The sponsor reported gastrointestinal disorders in 2 participants (5.9%). Reversible peripheral neuropathy is a clinically limiting toxicity of chronic DCA exposure.

Source: [Saol Therapeutics](https://saolrx.com/pipeline); [Stacpoole et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12450258/); [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf); [Saol Therapeutics UMDF Mitochondrial Medicine 2025 poster announcement (2025)](https://saolrx.com/saol-therapeutics-announces-poster-presentation-at-the-umdf-mitochondrial-medicine-2025-conference/); [Stacpoole et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31208525/)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Sodium dichloroacetate

No evidence found.

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

SL1009 remains investigational. The FDA found the original application insufficient to establish effectiveness and rejected the proposed external-control survival comparison as a basis for assessing treatment effect. The sponsor subsequently reported resubmission on June 30, 2026, acceptance as a complete Class 2 response, and a target FDA action date of December 30, 2026. Acceptance for review is not approval. Ketogenic dietary therapy remains a recommended treatment for primary PDCD; the evidence in this report does not establish that SL1009 should replace it.

Source: [FDA Orphan Drug Designations and Approvals (1990)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=45290); [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf); [Saol Therapeutics NDA resubmission acceptance announcement (2026)](https://www.prnewswire.com/news-releases/saol-therapeutics-announces-the-acceptance-of-resubmission-of-sl1009-dca-by-the-fda-with-pdufa-date-of-dec-30-2026-302836586.html); [Ganetzky et al. (2021)](https://www.ncbi.nlm.nih.gov/books/NBK571223/); [Stacpoole et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12450258/)

## Related pages
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Terms and abbreviations](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/terms-and-abbreviations.md)
- [SL1009 (sodium dichloroacetate): Pyruvate dehydrogenase complex deficiency](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/executive-summary) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/executive-summary.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Product information and disease description](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/product-information-and-disease-description.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Clinical evidence](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/clinical-evidence.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Economic information and modeling report](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/economics) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/economics.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: References](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/references) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/references.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: prevalence by geography](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/prevalence) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/prevalence.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/cost-effectiveness-analyses.md)
